Bird & Bird advises BrainEver on its €33 million Series B funding round

International law firm Bird & Bird advised BrainEver, a French biotech company specialised in the development of new therapies for patients with age-related neurodegenerative diseases, on its €33 million Series B fundraising round to fight Charcot's disease.

Critical Path Ventures and the European Innovation Council (EIC) led this new financing round, in which existing investors Ibionext and Relyens also participated.

With this new funding, the French biotech company, co-founded in 2015 by Bernard Gilly, CEO, and Professor Alain Prochiantz, Scientific Director (Collège de France), aims to launch a Phase I/II clinical trial by the end of 2025 for its innovative treatment targeting amyotrophic lateral sclerosis (ALS), more commonly known as Charcot's disease.

Bird & Bird advised BrainEver on this transaction with a team composed of Emmanuelle Porte, partner and Elodie Vardon, associate.

EIC was assisted by Bignon Lebray, with a team comprising Alexandre Ghesquière, partner, and Martin Wartelle, associate, and Critical Path Ventures was assisted by AGN Avocats, with a team comprising Emel Ozdemir and Antonin Cubertafond, partners.

News & Deals

More News & Deals
Deal Bird & Bird advises Ryde Group on Strategic EV Investment in Atoll Discovery

Aug 19 2025

Read More
Deal Bird & Bird advises MyRepublic on Strategic Broadband Sale to StarHub

Aug 15 2025

Read More
Deal Bird & Bird advises Theon on the acquisition of Kappa Optronics

Aug 12 2025

Read More
Deal Bird & Bird advises shareholders of The Payments Association on partnership with Nineteen Group

Aug 07 2025

Read More
Deal Bird & Bird acts for Cornerstone Investors in US$140m placing by Rockhopper Exploration

Aug 06 2025

Read More
News Bird & Bird boosts Dispute Resolution team in Singapore

Aug 06 2025

Read More